Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream

Por Ocvirk, Janja
Publicado em 2010

Malignant gliomas: old and new systemic treatment approaches

Por Mesti, Tanja, Ocvirk, Janja
Publicado no Radiol Oncol (2016)

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of...

Por Skof, Erik, Rebersek, Martina, Hlebanja, Zvezdana, Ocvirk, Janja
Publicado em 2009

Cetuximab in preoperative treatment of rectal cancer – term outcome of the XERT trial

Por Velenik, Vaneja, Ocvirk, Janja, Oblak, Irena, Anderluh, Franc
Publicado em 2012

A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis

Por Ocvirk, Janja, Heeger, Steffen, McCloud, Philip, Hofheinz, Ralf-Dieter
Publicado em 2013

The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rect...

Por Oblak, Irena, Velenik, Vaneja, Anderluh, Franc, Mozina, Barbara, Ocvirk, Janja
Publicado em 2013

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience

Por Mesti, Tanja, Moltara, Maja Ebert, Boc, Marko, Rebersek, Martina, Ocvirk, Janja
Publicado no Radiol Oncol (2015)

The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement

Por Mesti, Tanja, Boshkoska, Biljana Mileva, Kos, Mitja, Tekavčič, Metka, Ocvirk, Janja
Publicado no Radiol Oncol (2015)

Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II or III

Por Oblak, Irena, Anderluh, Franc, Velenik, Vaneja, Mozina, Barbara, Ocvirk, Janja, Ciric, Eva, Podvrsnik, Natasa Hrovatic
Publicado em 2011

Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer – a single institution retrospective analysis...

Por Rebersek, Martina, Boc, Marko, Cerkovnik, Petra, Benedik, Jernej, Hlebanja, Zvezdana, Volk, Neva, Novakovic, Srdjan, Ocvirk, Janja
Publicado em 2011

Metabolic Impact of Anti-Angiogenic Agents on U87 Glioma Cells

Por Mesti, Tanja, Savarin, Philippe, Triba, Mohamed N., Le Moyec, Laurence, Ocvirk, Janja, Banissi, Claire, Carpentier, Antoine F.
Publicado em 2014

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience

Por Ocvirk, Janja, Moltara, Maja Ebert, Mesti, Tanja, Boc, Marko, Rebersek, Martina, Volk, Neva, Benedik, Jernej, Hlebanja, Zvezdana
Publicado no Radiol Oncol (2016)

Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study

Por Velenik, Vaneja, Ocvirk, Janja, Music, Maja, Bracko, Matej, Anderluh, Franc, Oblak, Irena, Edhemovic, Ibrahim, Brecelj, Erik, Kropivnik, Mateja, Omejc, Mirko
Publicado em 2011

Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors

Por Hofheinz, Ralf-Dieter, Deplanque, Gaël, Komatsu, Yoshito, Kobayashi, Yoshimitsu, Ocvirk, Janja, Racca, Patrizia, Guenther, Silke, Zhang, Jun, Lacouture, Mario E., Jatoi, Aminah
Publicado no Oncologist (2016)

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

Por Ocvirk, Janja, Brodowicz, Thomas, Wrba, Fritz, Ciuleanu, Tudor E, Kurteva, Galina, Beslija, Semir, Koza, Ivan, Pápai, Zsuzsanna, Messinger, Diethelm, Yilmaz, Ugur, Faluhelyi, Zsolt, Yalcin, Suayib, Papamichael, Demetris, Wenczl, Miklós, Mrsic-Krmpotic, Zrinka, Shacham-Shmueli, Einat, Vrbanec, Damir, Esser, Regina, Scheithauer, Werner, Zielinski, Christoph C
Publicado em 2010